Saskia Schols

Dr. Saskia Schols

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 November 2020 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Open access
PDF file
SHShermarke Hassan
Shermarke Hassan
RMRory C. Monahan
Rory C. Monahan
EMEvelien P. Mauser‐Bunschoten
Evelien P. Mauser‐Bunschoten
LVLize van Vulpen
Lize van Vulpen
JEJeroen Eikenboom
Jeroen Eikenboom
SGSamantha C. Gouw
Samantha C. Gouw
Background Treatment of patients with hemophilia has advanced over the past decades, but it is unknown whether this has resulted in a normal life expectancy in the Netherlands. Objective This observational cohort study aimed to assess all‐cause and cause‐specific mortality in patients with hemophilia in the Netherlands between 2001‐2018 and to compare mortality and life‐expectancy with previous survival assessments from 1973 onwards. Patients/methods All 1066 patients with hemophilia who participated in a nationwide survey in 2001 were followed until July 2018. Results Information on 1031 individuals (97%) was available, of whom 142 (14%) deceased during follow‐up. Compared with the general Dutch male population, mortality of patients with hemophilia was still increased (standardized mortality ratio: 1.4, 95% confidence interval: 1.2‐1.7). Intracranial bleeding and malignancies were the most common causes of death. Estimated median life expectancy of patients with hemophilia was 77 years, six years lower than the median life expectancy of the general Dutch male population (83 years). Over the past 45 years, death rates of patients with hemophilia have consistently decreased, approaching the survival experience of the general population. Over the past decades, mortality due to human immunodeficiency virus and hepatitis C virus infections has decreased, death due to intracranial hemorrhages has increased and death due to ischemic heart disease has remained consistently low over time. Conclusions Survival in patients with hemophilia in the Netherlands has improved over time but is still lower than that of the general population.

12 June 2021 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Open access
PDF file
SHShermarke Hassan
Shermarke Hassan
EBErna C. van Balen
Erna C. van Balen
CSCees Smit
Cees Smit
EMEvelien P. Mauser‐Bunschoten
Evelien P. Mauser‐Bunschoten
LVLize van Vulpen
Lize van Vulpen
SGSamantha C. Gouw
Samantha C. Gouw
Introduction We conducted six cross-sectional nationwide questionnaire studies among all patients with hemophilia in the Netherlands from 1972 until 2019 to assess how health outcomes have changed, with a special focus on patients >50 years of age. Methods Data were collected on patient characteristics, treatment, (joint) bleeding, joint impairment, hospitalizations, human immunodeficiency virus and hepatitis C infections, and general health status (RAND-36). Results In 2019, 1009 patients participated of whom 48% had mild, 15% moderate and 37% severe hemophilia. From 1972 to 2019, the use of prophylaxis among patients with severe hemophilia increased from 30% to 89%. Their median annual bleeding rate decreased from 25 to 2 bleeds. Patients with severe hemophilia aged 40 years joint status did not improve. In 2019, 5% of all 1009 patients were positive for the human immunodeficiency virus. The proportion of patients with an active hepatitis C infection drastically decreased from 45% in 2001 to 2% in 2019 due to new anti-hepatitis C treatment options. Twenty-five percent had significant liver fibrosis even after successful therapy. Compared with the general male population, patients aged >50 years reported much lower scores on the RAND-36, especially on physical functioning. Discussion/Conclusion Our study shows that increased use of prophylactic treatment and effective hepatitis C treatment have improved joint health and nearly eradicated hepatitis C infection in patients with hemophilia in the Netherlands. However, patients still suffer from hemophilia-related complications, especially patients aged >50 years.

4 April 2024 in Blood
Verified
Journal Article
Open access
PDF file
FAFerdows Atiq
Ferdows Atiq
RBRobin Blok
Robin Blok
CKCalvin B. van Kwawegen
Calvin B. van Kwawegen
DDDearbhla Doherty
Dearbhla Doherty
MLMichelle Lavin
Michelle Lavin
JOJames O'Donnell
James O'Donnell
There is significant ongoing debate regarding type 1 von Willebrand disease (VWD) defintion. Previous guidelines recommended patients with von Willebrand factor (VWF) levels <30 IU/dL be diagnosed type 1 VWD, whereas patients with significant bleeding and VWF levels from 30 to 50 IU/dL be diagnosed with low VWF. To elucidate the relationship between type 1 VWD and low VWF in the context of age-induced increases in VWF levels, we combined data sets from 2 national cohort studies: 162 patients with low VWF from the Low VWF in Ireland Cohort (LoVIC) and 403 patients with type 1 VWD from the Willebrand in The Netherlands (WiN) studies. In 47% of type 1 VWD participants, VWF levels remained 50 IU/dL) in 23% of type 1 VWD cases. Crucially, absolute VWF antigen (VWF:Ag) levels and increase of VWF:Ag per year overlapped between low VWF and normalized type 1 VWD participants. Moreover, multiple regression analysis demonstrated that VWF:Ag levels in low VWF and normalized type 1 VWD patients would not have been different had they been diagnosed at the same age (β = 0.00; 95% confidence interval, −0.03 to 0.04). Consistently, no difference was found in the prevalence of VWF sequence variants; factor VIII activity/VWF:Ag or VWF propeptide/VWF:Ag ratios; or desmopressin responses between low VWF and normalized type 1 VWD patients. In conclusion, our findings demonstrate that low VWF does not constitute a discrete clinical or pathological entity. Rather, it is part of an age-dependent type 1 VWD evolving phenotype. Collectively, these data have important implications for future VWD classification criteria.

28 January 2022 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Open access
PDF file
MVMarieke J.A. Verhagen
Marieke J.A. Verhagen
LVLars L.F.G. Valke
Lars L.F.G. Valke
SSSaskia Schols
Saskia Schols
Patients with severe hemophilia A (HA) have an increased risk of spontaneous and trauma-related bleeding due to a congenital absence of factor VIII (FVIII). Most severe HA patients use prophylactic FVIII concentrate which effect can be monitored with FVIII activity level measurement. However, FVIII activity level is less valuable in predicting the potential clinical bleeding risk. Some patients still experience breakthrough bleeds despite adequate FVIII trough levels, while others do not bleed with trough levels below threshold. This difference may be caused by inter-individual differences in pro- and anticoagulant factors, the so-called hemostatic balance. Thrombin generation assays (TGAs) measure the hemostatic balance as a whole. Thereby, the TGA may be a better tool in the guidance and monitoring of treatment in HA patients. In addition, TGAs offer the opportunity to determine the response to bypassing agents (BPAs) and treatment with non-factor replacement therapy, where FVIII activity assays are not suitable for monitoring. This review summarizes the current knowledge about monitoring different HA treatment modalities by TGA, as single treatment option and when used in a concomitant fashion.

10 July 2021 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Open access
PDF file
EBErna C. van Balen
Erna C. van Balen
LHLotte Haverman
Lotte Haverman
SHShermarke Hassan
Shermarke Hassan
ETElisabeth M. Taal
Elisabeth M. Taal
CSCees Smit
Cees Smit
SGSamantha C. Gouw
Samantha C. Gouw
Background and purpose The PROMIS Profile-29 questionnaire is widely used worldwide, but it has not yet been validated in the Netherlands, nor in persons with hemophilia. The aim of this study was to validate the Dutch-Flemish version of the PROMIS-29 Profile v2.01 in adults with hemophilia. Methods Dutch males with hemophilia (all severities) completed questionnaires that contained socio-demographic and clinical characteristics, the PROMIS-29, RAND-36, and the Hemophilia Activities List (HAL). Structural validity of each subscale was assessed with Confirmatory Factor Analysis (CFA). Internal consistency was calculated for each subscale with sufficient model fit in CFA. Construct validity was assessed by testing hypotheses about 1) correlations of each PROMIS-29 subscale with corresponding scales of RAND-36 and domains of HAL, and 2) mean differences in T-scores between subgroups with different hemophilia severities, self-reported joint impairment, and hiv infection status. We considered ≥75 percent of data in accordance with the hypotheses evidence for construct validity. Results In total, 770 persons with hemophilia participated in this cross-sectional study. CFA revealed sufficient structural validity for five subscales: Physical Function, Depression, Sleep Disturbance, Ability to Participate in Social Roles and Activities and Pain Interference. Internal consistency was high and Cronbach’s alpha ranged from 0.79 for Sleep Disturbance to 0.96 for Pain Interference. Differences between clinical subgroups were in the expected direction. Construct validity was confirmed for Physical Function, Anxiety, Depression, Fatigue, Sleep Disturbance, and Pain Intensity. Conclusion This study revealed sufficient evidence for structural validity, internal consistency, and construct validity for most PROMIS Profile-29 subscales among people with hemophilia in the Netherlands.

20 September 2022 in Blood Advances
Verified
Journal Article
Open access
PDF file
FAFerdows Atiq
Ferdows Atiq
JHJessica Maria Heijdra
Jessica Maria Heijdra
FSFleur Snijders
Fleur Snijders
JBJohan Boender
Johan Boender
EKEva Kempers
Eva Kempers
FLFrank W. G. Leebeek
Frank W. G. Leebeek
Patients with type 1 and type 2 von Willebrand disease (VWD) can be treated with desmopressin. Although a previous study has shown that the location of the causative VWF gene variant is associated with desmopressin response in type 1 VWD, the association between variants in the VWF gene and desmopressin response is not yet fully understood. Our primary aim was to compare desmopressin response in type 1 VWD patients with and without a VWF gene variant. Secondly, we investigated whether desmopressin response depends on specific VWF gene variants in type 1 and type 2 VWD. We included 250 patients from the Willebrand in the Netherlands study: 72 type 1 without a VWF gene variant, 108 type 1 with a variant, 45 type 2A, 16 type 2M, and 9 type 2N patients. VWF gene was analyzed with ion semiconductor sequencing and Multiplex Ligation-dependent Probe Amplification. Complete response to desmopressin was observed in all type 1 VWD patients without a variant, 64.3% of type 1 patients with a variant, and 31.3% of type 2 patients (P < .001). Despite a large interindividual variability in desmopressin response, patients with the same variant had comparable desmopressin responses. For instance, in 6 type 1 patients with exon 4 to 5 deletion, mean VWF activity at 1 hour after desmopressin was 0.81 IU/mL, with a coefficient of variation of 22.9%. In conclusion, all type 1 VWD patients without a VWF gene variant respond to desmopressin. In type 1 and type 2 VWD patients with a VWF variant, desmopressin response highly depends on the VWF gene variants.